Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders

Bibliography

• Kessler RC, Ruscio AM, Shear K, Wittchen HU. Epidemiology of anxiety disorders. Curr Top Behav Neurosci 2010;2:21–35
   PubMedGoogle Scholar
• Dell’Osso B, Camuri G, Benatti B, et al. Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder. Early Interv Psychiatry 2013;7:374–80
   PubMed Web of Science ®Google Scholar
• Altamura AC. Drug-resistance phenomena in major psychoses: their discrimination and causal mechanisms. Clin Neuropharmacol 1990;13:1–15
   PubMed Web of Science ®Google Scholar
• Irons J. Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat 2005;1:289–99
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th revision (DSM-5). American Psychiatric Press; Washington, DC:2013
   Google Scholar
• Saletu B, Schjerve M, Grünberger J, et al. Fluvoxamine-a new serotonin re-uptake inhibitor: first clinical and psychometric experiences in depressed patients. J Neural Transm 1977;41:17–36
   PubMed Web of Science ®Google Scholar
• Bertrams K, Coupain N, Homburg E. Solvay history of a multinational family firm. Cambridge University Press; New York: 2013
   Google Scholar
• Food and Drug Administration. Antidepressant Use in Children, Adolescents, and Adults. 2007. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/UCM096273
   Google Scholar
• Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol 2013;4:45
   Google Scholar
• Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract 2006;60:482–91
   PubMed Web of Science ®Google Scholar
• Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996;307:117–19
   PubMed Web of Science ®Google Scholar
• Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009;124:195–206
   PubMed Web of Science ®Google Scholar
• Cobos EJ, Entrena JM, Nieto FR, et al. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 2008;6(4):344–66
   PubMed Web of Science ®Google Scholar
• Furuse T, Hashimoto K. Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors. Ann Gen Psychiatry 2009;8:26
   PubMedGoogle Scholar
• Niitsu T, Iyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr Pharm Des 2012;18:875–83
   PubMed Web of Science ®Google Scholar
• Stahl SM. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry 2008;69:1673–4
   PubMed Web of Science ®Google Scholar
• van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995;29:1–9
   PubMedGoogle Scholar
• Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994;27:175–90
   PubMed Web of Science ®Google Scholar
• Härtter S, Wetzel H, Hammes E, et al. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit 1998;20:446–9
   PubMed Web of Science ®Google Scholar
• Benmansour S, Piotrowski JP, Altamirano AV, Frazer A. Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine. Neuropsychopharmacology 2009;34:555–64
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Sugai T, Fukui N, et al. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol 2011;25:908–14
   PubMed Web of Science ®Google Scholar
• DeVane CL, Gill HS. Clinical pharmaockinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry 1997;58:7–14
   PubMed Web of Science ®Google Scholar
• Orlando R, De Martin S, Andrighetto L, et al. Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. Br J Clin Pharmacol 2010;69:279–86
   PubMed Web of Science ®Google Scholar
• Overmars H, Scherpenisse PM, Post LC. Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet 1983;8:269–80
   PubMed Web of Science ®Google Scholar
• Miura M, Ohkubo T. Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine. Xenobiotica 2007;37:169–79
   PubMed Web of Science ®Google Scholar
• Olesen OV, Linnet K. Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000;20:35–42
   PubMed Web of Science ®Google Scholar
• Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002;71:141–52
   PubMed Web of Science ®Google Scholar
• Piontek CM, Wisner KL, Perel JM, Peindl KS. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry 2001;62:111–13
   PubMed Web of Science ®Google Scholar
• Hendrick V, Fukuchi A, Altshuler L, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001;179:163–6
   PubMed Web of Science ®Google Scholar
• van Harten J, Duchier J, Devissaguet JP, et al. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet 1993;24:177–82
   PubMed Web of Science ®Google Scholar
• Orlando R, Padrini R, Perazzi M, et al. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther 2006;79:489–99
   PubMed Web of Science ®Google Scholar
• Labellarte M, Biederman J, Emslie G, et al. Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents. J Am Acad Child Adolesc Psychiatry 2004;43:1497–505
   PubMed Web of Science ®Google Scholar
• Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on Fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995;58:399–403
   PubMed Web of Science ®Google Scholar
• Katoh Y, Uchida S, Kawai M, et al. Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Biol Pharm Bull 2010;33:285–8
   PubMed Web of Science ®Google Scholar
• Gerstenberg G, Aoshima T, Fukasawa T, et al. Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Ther Drug Monit 2003;25:463–8
   PubMed Web of Science ®Google Scholar
• LLerena A, Naranjo ME, Rodrigues-Soares F, et al. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol 2014;10:1569–83
   PubMed Web of Science ®Google Scholar
• Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229–43
   PubMed Web of Science ®Google Scholar
• Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001;23:410–13
   PubMed Web of Science ®Google Scholar
• Chiu CC, Lane HY, Huang MC, et al. Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol 2004;44:1385–90
   PubMed Web of Science ®Google Scholar
• Wang CY, Zhang ZJ, Li WB, et al. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol 2004;44:785–92
   PubMed Web of Science ®Google Scholar
• Albers LJ, Ozdemir V, Marder SR, et al. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol 2005;25:170–4
   PubMed Web of Science ®Google Scholar
• DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry 1998;59:85–93
   PubMed Web of Science ®Google Scholar
• Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol 2012;68:29–37
   PubMed Web of Science ®Google Scholar
• Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 1997;33:454–71
   PubMed Web of Science ®Google Scholar
• Vezmar S, Miljkovic B, Vucicevic K, et al. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. J Pharmacol Sci 2009;110:98–104
   PubMed Web of Science ®Google Scholar
• Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50:884–95
   PubMed Web of Science ®Google Scholar
• Fornaro M. Agomelatine in the treatment of panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:286–7
   PubMed Web of Science ®Google Scholar
• De Berardis D, Conti CM, Marini S, et al. Is there a role for agomelatine in the treatment of anxiety disorders? A review of published data. Int J Immunopathol Pharmacol 2013;26:299–304
   PubMed Web of Science ®Google Scholar
• Buoli M, Mauri MC, Altamura AC. Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder. Expert Opin Drug Metab Toxicol 2014;10:885–92
   PubMed Web of Science ®Google Scholar
• Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998;26:572–5
   PubMed Web of Science ®Google Scholar
• Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73–8
   PubMed Web of Science ®Google Scholar
• Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008;30:1206–27
   PubMed Web of Science ®Google Scholar
• Sugahara H, Maebara C, Ohtani H, et al. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. Eur J Clin Pharmacol 2009;65:699–704
   PubMed Web of Science ®Google Scholar
• Vlase L, Popa A, Neag M, et al. Effect of fluvoxamine on the pharmacokinetics of zolpidem: a two-treatment period study in healthy volunteers. Clin Exp Pharmacol Physiol 2012;39:9–12
   PubMed Web of Science ®Google Scholar
• van Harten J, Stevens LA, Raghoebar M, et al. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther 1992;52:427–35
   PubMed Web of Science ®Google Scholar
• Milijkovic BR, Pokrajac M, Timotijevic I, et al. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy. Int Clin Psychopharmacol 1997;12:207–12
   PubMed Web of Science ®Google Scholar
• Ochs HR, Greenblatt DJ, Verburg-Ochs B, et al. Chronic treatment with fluvoxamine, clovoxamine and placebo: interaction with digoxin and effects on sleep and alertness. J Clin Pharmacol 1989;29:91–5
   PubMed Web of Science ®Google Scholar
• Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 2008;47:191–202
   PubMed Web of Science ®Google Scholar
• Paulzen M, Finkelmeyer A, Grözinger M. Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients. Pharmacopsychiatry 2011;44:317–23
   PubMed Web of Science ®Google Scholar
• Saruwatari J, Yasui-Furukori N, Niioka T, et al. Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers. J Clin Psychopharmacol 2012;32(2):195–9
   PubMed Web of Science ®Google Scholar
• Andrade C. Selective serotonin reuptake inhibitor drug interactions in patients receiving statins. J Clin Psychiatry 2014;75:e95–9
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311–20
   PubMed Web of Science ®Google Scholar
• Njung’e K, Handley SL. Effects of 5-HT uptake inhibitors, agonists and antagonists on burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol 1991;104:105–12
   PubMed Web of Science ®Google Scholar
• Olivier B, Bosch L, van-Hest A, et al. Preclinical evidence on the psychotropic profile of fluvoxamine. Pharmacopsychiatry 1993;26:2–9
   PubMedGoogle Scholar
• Woods A, Smith C, Szewczak M, et al. Selective serotonin reuptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology (Berl) 1993;112:195–8
   PubMed Web of Science ®Google Scholar
• Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321–6
   PubMed Web of Science ®Google Scholar
• Sandmann J, Lörch B, Bandelow B, et al. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry 1998;31:117–21
   PubMed Web of Science ®Google Scholar
• Asnis GM, Hameedi FA, Goddard AW, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 2001;103:1–14
   PubMed Web of Science ®Google Scholar
• Spiegel DA, Saeed SA, Bruce TJ. An open trial of fluvoxamine therapy for panic disorder complicated by depression. J Clin Psychiatry 1996;57:37–40
   PubMed Web of Science ®Google Scholar
• Goddard AW, Woods SW, Sholomskas DE, et al. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 1993;48:119–33
   PubMed Web of Science ®Google Scholar
• den Boer JA, Westenberg HG, Kamerbeek WD, et al. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21–32
   PubMed Web of Science ®Google Scholar
• Bakish D, Hooper CL, Filteau MJ, et al. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996;32:135–41
   PubMed Web of Science ®Google Scholar
• Nair NP, Bakish D, Saxena B, et al. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety 1996;2:192–8
   PubMedGoogle Scholar
• Den Boer JA, Westenberg HG. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990;102:85–94
   PubMed Web of Science ®Google Scholar
• Den Boer JA, Westenberg HG. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3:59–74
   PubMed Web of Science ®Google Scholar
• van Vliet IM, den Boer JA, Westenberg HG, Slaap BR. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol 1996;16:299–306
   PubMed Web of Science ®Google Scholar
• Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol 2001;21:335–9
   PubMed Web of Science ®Google Scholar
• Dannon PN, Iancu I, Lowengrub K, et al. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol 2007;30:326–34
   PubMed Web of Science ®Google Scholar
• Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44–50
   PubMed Web of Science ®Google Scholar
• Sharp DM, Power KG, Simpson RJ, et al. Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract 1997;47(416):150–5
   PubMed Web of Science ®Google Scholar
• de Beurs E, van Balkom AJ, Lange A, et al. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995;152:683–91
   PubMed Web of Science ®Google Scholar
• Azhar MZ. Comparison of Fluvoxamine alone, Fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan – implications for management by family doctors. Med J Malaysia 2000;55:402–8
   PubMedGoogle Scholar
• Wylie ME, Miller MD, Shear MK, et al. Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial data. J Geriatr Psychiatry Neurol 2000;13:43–8
   PubMed Web of Science ®Google Scholar
• Walkup J, Labellarte M, Riddle MA, et al. Research Units on Pediatric Psychopharmacology Anxiety Study Group. Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. J Child Adolesc Psychopharmacol 2002;12:175–88
   PubMed Web of Science ®Google Scholar
• Hedges DW, Brown BL, Shwalb DA, et al. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 2007;21:102–11
   PubMed Web of Science ®Google Scholar
• van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994;115:128–34
   PubMed Web of Science ®Google Scholar
• DeVane CL, Ware MR, Emmanuel NP, et al. Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia. Int Clin Psychopharmacol 1999;14:345–51
   PubMed Web of Science ®Google Scholar
• Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999;156:756–60
   PubMed Web of Science ®Google Scholar
• Stein DJ, Westenberg HG, Yang H, et al. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2003;6:317–23
   PubMed Web of Science ®Google Scholar
• Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24:118–25
   PubMed Web of Science ®Google Scholar
• Westenberg HG, Stein DJ, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24:49–55
   PubMed Web of Science ®Google Scholar
• Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2007;10:263–74
   PubMed Web of Science ®Google Scholar
• Walkup J, Labellarte M, Riddle MA, et al. Research Units on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med 2001;344:1279–85
   PubMed Web of Science ®Google Scholar
• Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol 2013;28:33–45
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gaynes BN, Gartlehner G, et al. Efficacy and tolerability of second-generation antidepressants in social anxiety disorder. Int Clin Psychopharmacol 2008;23:170–9
   PubMed Web of Science ®Google Scholar
• Bandelow B, Sher L, Bunevicius R, et al. WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 2012;16:77–84
   PubMed Web of Science ®Google Scholar
• Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand 1990;81:185–9
   PubMed Web of Science ®Google Scholar
• Buoli M, Dell’osso B, Bosi MF, Altamura C. Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial. Psychiatry Clin Neurosci 2010;64:612–19
   PubMed Web of Science ®Google Scholar
• Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014;75:e441–9
   PubMed Web of Science ®Google Scholar
• Gabriel A. Serotonin reuptake inhibitor and fluvoxamine-induced severe hyponatremia in a 49-year-old man. Case Rep Med 2009;2009:585193
   Google Scholar
• Teichert M, Visser LE, Uitterlinden AG, et al. Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Clin Pharmacol 2011;72:798–805
   PubMed Web of Science ®Google Scholar
• Henry JA. Overdose and safety with fluvoxamine. Int Clin Psychopharmacol 1991;6:41–5
   PubMed Web of Science ®Google Scholar
• Pacek LR, Storr CL, Mojtabai R, et al. Comorbid alcohol dependence and anxiety disorders: a national survey. J Dual Diagn 2013;9:(4).10.1080/15504263.2013.835164
   PubMed Web of Science ®Google Scholar
• Buoli M, Caldiroli A, Caletti E, et al. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin Pharmacother 2013;14:175–84
   PubMed Web of Science ®Google Scholar
• Abraham G, Nair C, Tracy JI, et al. The effects of clozapine on symptom clusters in treatment-refractory patients. J Clin Psychopharmacol 1997;17:49–53
   PubMed Web of Science ®Google Scholar
• Matsumoto R, Kitabayashi Y, Nakatomi Y, et al. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Am J Psychiatry 2005;162:812
   PubMed Web of Science ®Google Scholar
• Hori T, Makabe K, Nemoto K, Asada T. Hypersalivation induced by olanzapine with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:758–60
   PubMed Web of Science ®Google Scholar
• Ng W, Kennar R, Uetrecht J. Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis. Chem Res Toxicol 2014;27:1104–8
   PubMed Web of Science ®Google Scholar
• de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005;46:262–73
   PubMed Web of Science ®Google Scholar
• Nayyar N. Serotonin syndrome associated with sertraline, trazodone and tramadol abuse. Indian J Psychiatry 2009;51:68
   PubMedGoogle Scholar
• Perse TL, Greist JH, Jefferson JW, et al. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1987;144:1543–8
   PubMed Web of Science ®Google Scholar